CG
NAMSW icon

Cutler Group’s NewAmsterdam Pharma Warrant NAMSW Stock Holding History

Cutler Group’s Portfolio NAMSW Stock Details NAMSW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,960
Closed -$15K – 3130
2023
Q4 		$15K Hold
4,960
– – ﹤0.01% 2136
2023
Q3 		$9K Hold
4,960
– – ﹤0.01% 2533
2023
Q2 		$10K Buy
+4,960
New +$10.7K ﹤0.01% 2261

Other funds holding NAMSW

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
VI
Vestcor Inc Fredericton, New Brunswick, Canada $3.63B AUM 21.49% 1-Year Est. Return

Cutler Group's NAMSW Position: Q1 2024 in Review

Cutler Group sold out of NewAmsterdam Pharma Warrant (NAMSW) in Q1 2024, closing a stake of 4,960 shares — an estimated $15K sold.

Cutler Group first reported a position in NAMSW in Q2 2023 and held it in 3 quarters. The position peaked at $15K in Q4 2023. 11 funds tracked by Wall St. Rank hold NAMSW as of Q1 2024.

  • Cutler Group reported no remaining NewAmsterdam Pharma Warrant position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 4,960 NewAmsterdam Pharma Warrant shares in Q1 2024, an estimated $15K.
  • Cutler Group first reported a position in NewAmsterdam Pharma Warrant in Q2 2023 and held it in 3 quarters.
  • Cutler Group's NewAmsterdam Pharma Warrant position peaked at $15K in Q4 2023.
  • 11 funds tracked by Wall St. Rank held NewAmsterdam Pharma Warrant as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.